Payment & Shipping Terms | Supply Capacity |
Payment Terms: | T/T, WU | Production Capacity: | 500kg/year |
Min. Order: | 1 Gram | Packing: | according to the customer's requirements |
Means of Transport: | Ocean, Air, Land | Delivery Date: | 7 days |
Voglibose
CAS: 83480-29-9
Voglibose is an oral fall blood sugar medicine, can improve postprandial hyperglycemia and diabetes by takeda Japanese company successfully developed, belongs to the alpha glycosidase inhibitor (carbohydrates to delay intestinal drug absorption and achieves hypoglycemic effect), the mechanism of action is in intestine inhibits the disaccharides broken down into simple sugars disaccharides class hydrolase (alpha glycosidase enzymes), and thus delay the digestion and absorption of sugar, so as to improve the postprandial hyperglycemia. Health adults give sugar determination of load after exhaled hydrogen, the results confirmed that the dosage of this drug in clinical under has inhibitory effect on blood glucose increased. Normal rat oral medicine, this product after the inhibition of starch and sucrose, maltose load increased blood sugar, lactose and glucose, fructose and to Portugal after load increased blood sugar without inhibition. In vitro test mechanism, according to a study for the maltase from swine and rat small intestine and sucrase, this inhibitory effect is stronger; On the other hand, the pigs and rats alpha inhibition of pancreatic amylase.
Application: Used in the treatment of diabetes
